Key Developments: Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

3,551.65INR
11:02pm EST
Price Change (% chg)

Rs-17.75 (-0.50%)
Prev Close
Rs3,569.40
Open
Rs3,558.00
Day's High
Rs3,566.10
Day's Low
Rs3,535.00
Volume
663
Avg. Vol
20,061
52-wk High
Rs3,581.70
52-wk Low
Rs2,250.00

Search Stocks

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Laboratories Ltd announces launch of Sumatriptan Injection USP, autoinjector systemi
Wednesday, 26 Feb 2014 12:43am EST 

Dr.Reddy's Laboratories Ltd:Has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For Subcutaneous Use.Says injection was launched In the US market on Feb. 25, 2014, following the approval by the United States Food & Drug Administration.  Full Article

Dr.Reddy's Laboratories Ltd Faces Patent Infringement Suit - Business Standard
Tuesday, 5 Nov 2013 09:34am EST 

Business Standard reported that the Teijin Limited, owner of the US patent of hyperuricemia drug febuxostat, along with the two licence holders of the patent, has filed an infringement suit against Dr.Reddy's Laboratories Ltd for seeking to manufacture and sell a generic version of the drug in the US before the expiration of the patent.  Full Article

Department of Pharmaceuticals Rejects Drug Price Review Pleas of Dr.Reddy's Laboratories Ltd - Business Standard
Tuesday, 29 Oct 2013 08:50am EDT 

Business Standard reported that the Department of Pharmaceuticals has rejected a review petition filed by Dr.Reddy's Laboratories Ltd and Abbott Healthcare, on ceiling of prices on their products. On May 15, 2013, the Department of Pharmaceuticals released drugs (price control) order, governing the price control mechanism for 348 drugs in the national list. As per this order, the prices of each of the drugs are determined on the average of all drugs having an Indian market share of over 1% by value. The individual drug price notifications are being released in a phased manner by the National Pharmaceutical Pricing Authority.  Full Article

Dr.Reddy's Laboratories Ltd Announces Approval of Azacitidine for Injection
Tuesday, 17 Sep 2013 02:13am EDT 

Dr.Reddy's Laboratories Ltd announced that Azacitidine for injection 100 mg/vial, a bioequivalent generic version of VIDAZA is approved by the USFDA on September 16, 2013.  Full Article

Dr.Reddy's Laboratories Ltd announces the Launch of Divalproex Sodium Extended - Release Tablets, USP
Thursday, 22 Aug 2013 08:30am EDT 

Dr.Reddy's Laboratories Ltd announced that it has launched Divalproex Sodium Extended - Release Tablets, USP (250 mg - 500mg), a therapeutic equivalent generic version of Depakote ER Tablet, Extended Release Tablets, USP was approved by the United Stated Food & Drug Administration (USFDA).  Full Article

Dr.Reddy's Laboratories Ltd Appoints Dr. Sripada Chandrasekhar As President And Global Head of Human Resources
Monday, 12 Aug 2013 03:38am EDT 

Dr.Reddy's Laboratories Ltd announced that the appointment Dr. Sripada Chandrasekhar as President and Global Head of Human Resources.  Full Article

Dr.Reddy's Laboratories Ltd Announces Launch Of Donepezil Hydrocholride Tablets
Saturday, 27 Jul 2013 03:58am EDT 

Dr.Reddy's Laboratories Ltd announced that it has launched Donepezil Hydrochloride Tablets, 23 mg, a therapeutic equivalent generic version of ARICEPT, 23 mg in the US market on July 26, 2013, following the approval by the United States Food and Drug Administration (USFDA) of Dr.Reddy's ANDA for Donepezil Hydrochloride Tablets, 23 mg.  Full Article

Dr.Reddy's Laboratories Ltd Announces Launch Of Lamotrigine Extended-Release Tablets
Wednesday, 26 Jun 2013 03:49am EDT 

Dr.Reddy's Laboratories announced that is has launched Lamotrigine Extended-Release Tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg) a therapeutic equivalent generic version of Lamictal XR (lamotrigine) in the US market on June 25, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Lamotrigine XR tablets. Dr. Reddy's Lamotrigine XR Tablets 25 mg, 50 mg, 100 mg, 200 mg, and 300 mg are available as unit of use bottles of 30s.  Full Article

Dr.Reddy's Laboratories Ltd Sued By AbbVie Inc For Infringement Of Thyroid Injection Patent-Business Line
Tuesday, 18 Jun 2013 08:00pm EDT 

Business Line reported that US-based drug maker AbbVie Inc, the spun-off entity of Abbott, has dragged Dr.Reddy's Laboratories Ltd to court for allegedly infringing the former’s patented drug Zemplar on six counts concerning three patents. The US drug maker requested the court to pass an order to restrain DRL from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing DRL’s generic paricalcitol injectable products prior to the expiration of the said patents.  Full Article

FUJIFILM Holdings Corp. And Dr.Reddy's Laboratories Ltd Call Off Joint Venture For Generic Drugs In Japan
Monday, 3 Jun 2013 02:10am EDT 

FUJIFILM Holdings Corp. And Dr.Reddy's Laboratories Ltd announced that they have decided to terminate the MoU to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan. Though the Memorandum of Understanding for generic drugs has been canceled, both the companies will explore partnerships in other related areas. DRL and Fujifilm signed a MoU on July 28, 2011 and the duo had conducted detailed studies on the establishment of a joint venture for developing and manufacturing generic drugs in Japan. However, as Fujifilm realigns its long-term growth strategy for the pharmaceutical business, both companies have come to a mutual agreement to terminate the MoU. The two companies will continue to explore partnership/ alliance opportunities in other pharmaceutical businesses such as API (active pharmaceutical ingredient) development and manufacturing, contract research and development and marketing of super-generics.  Full Article

Search Stocks